Compare
Cytek Biosciences, Inc. vs Pacific Biosciences of California, Inc. vs Quanterix Corp vs Harvard Bioscience Inc
| Latest fiscal year | Cytek Biosciences, Inc. CTKB | Pacific Biosciences of California, Inc. PACB | Quanterix Corp QTRX | Harvard Bioscience Inc HBIO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $201.49M | $160.00M | $138.90M | $86.55M |
| Revenue growth (YoY) | +0.5% | +3.9% | +1.1% | -8.1% |
| Gross margin | 51.8% | 28.6% | 46.8% | 57.7% |
| Operating margin | -20.0% | -346.2% | -90.4% | -56.1% |
| Net margin | -33.0% | -341.5% | -77.1% | -65.5% |
| Net income | -$66.54M | -$546.38M | -$107.15M | -$56.70M |
| EPS (Diluted) | n/a | -$1.82 | -$2.51 | -$1.28 |
| Operating cash flow | -$4.69M | -$111.21M | -$77.24M | $6.73M |
| Free cash flow | -$8.77M | -$113.92M | -$79.85M | $5.47M |
| Cash & equivalents | $90.85M | $63.71M | $29.84M | $8.61M |
| Total assets | $461.54M | $784.08M | $418.77M | $80.07M |
| Total liabilities | $119.80M | $778.73M | $123.04M | $66.34M |
| Shareholders' equity | $341.74M | $5.35M | $295.73M | $13.73M |
| Return on year-end equity | -19.5% | n/m | -36.2% | -412.8% |
| Shares outstanding | 128.55M | 301.96M | 46.74M | 44.72M |
Revenue, most recent five fiscal years
| Fiscal year | Cytek Biosciences, Inc. | Pacific Biosciences of California, Inc. | Quanterix Corp | Harvard Bioscience Inc |
|---|---|---|---|---|
| Latest | $201.49M Ended 2025-12-31 | $160.00M Ended 2025-12-31 | $138.90M Ended 2025-12-31 | $86.55M Ended 2025-12-31 |
| 1 year earlier | $200.45M Ended 2024-12-31 | $154.01M Ended 2024-12-31 | $137.42M Ended 2024-12-31 | $94.14M Ended 2024-12-31 |
| 2 years earlier | $193.01M Ended 2023-12-31 | $200.52M Ended 2023-12-31 | $122.37M Ended 2023-12-31 | $112.25M Ended 2023-12-31 |
| 3 years earlier | $164.04M Ended 2022-12-31 | $128.30M Ended 2022-12-31 | $105.52M Ended 2022-12-31 | $113.33M Ended 2022-12-31 |
| 4 years earlier | $127.95M Ended 2021-12-31 | $130.51M Ended 2021-12-31 | $110.56M Ended 2021-12-31 | $118.90M Ended 2021-12-31 |